|Bid||25.00 x 4000|
|Ask||25.59 x 1400|
|Day's Range||25.12 - 26.68|
|52 Week Range||6.02 - 29.80|
|Beta (5Y Monthly)||-3.29|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 02, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.32|
Subscribe to Yahoo Finance Plus to view Fair Value for PHVS
Key Insights Significant control over Pharvaris by private equity firms implies that the general public has more power...
ZUG, Switzerland, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the presentation of one oral session and two posters at the Global Allergy and Asthma Excellence Network (GA²LEN) Urticaria Centers of Reference and Excellence (UCARE) Conference, being held from December 7-9, 2023, at the Rebouças Convention Center in São Paulo, B
Data from a mid-stage study shows that treatment with Pharvaris' (PHVS) investigational HAE drug reduced the monthly attack rate by 84.5%.